Stryker Corporation
SYK
$0.00
+0.25%
Stryker Corporation is a leading global medical device company specializing in orthopedic implants, surgical equipment, and hospital beds. It is one of the top three players in reconstructive orthopedic implants and holds a leadership position in operating room equipment.
SYK
Stryker Corporation
$0.00
Related headlines
Investment Opinion: Should I buy SYK Today?
Based on a synthesis of the data, the objective assessment is a 'Hold'. While the company's fundamental performance is strong, with solid revenue growth and profitability, the stock's severe technical downtrend and elevated valuation multiples create significant near-term headwinds. The current price near 52-week lows may attract value-oriented investors, but a more attractive entry point or clearer signs of a technical reversal would be needed to justify a 'Buy' rating.
Sign up to view all
SYK 12-Month Price Forecast
The analysis yields a neutral stance due to the conflict between robust company fundamentals and poor stock price action. Confidence is medium as the path depends on whether fundamentals can overcome technical and valuation overhangs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
6 analysts
Implied Upside
—
vs. current price
Analyst Count
6
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for Stryker shows a consensus leaning positive, with recent actions including 'Buy' ratings from Needham and BTIG, and 'Outperform' from Bernstein. However, the provided data does not include a consensus target price or a full ratings distribution, indicating that while analyst sentiment is generally favorable, no sufficient quantitative consensus data is available for a detailed summary.
Bulls vs Bears: SYK Investment Factors
Stryker presents a dichotomy of strong fundamentals against a backdrop of severe technical weakness and high valuation. The company's solid revenue growth, profitability, and cash flow are offset by a stock price that has fallen sharply and trades at premium multiples. The current price near 52-week lows may reflect an overreaction, but valuation remains a key concern.
Bullish
- Strong Revenue Growth: Q4 revenue grew 11.4% YoY, indicating robust demand.
- Healthy Profitability Margins: Gross margin of 65.2% and net margin of 11.8% in Q4.
- Solid Financial Position: Strong current ratio of 1.89 and manageable debt-to-equity of 0.66.
- Robust Free Cash Flow: TTM free cash flow of $4.28B supports flexibility and returns.
Bearish
- Significant Technical Downtrend: Stock down 15.2% in past month, underperforming S&P 500.
- Elevated Valuation Multiples: Trailing P/E of 41.4 and EV/EBITDA of 23.0 are high.
- High PEG Ratio: PEG ratio of 5.16 suggests growth is priced in.
- Price Near 52-Week Low: Current price is only 2.9% above its 52-week low.
SYK Technical Analysis
Overall, the stock has been in a significant downtrend over the past six months, with a decline of 10.32%. The price action shows a sharp sell-off from a peak near $388 in late October 2025 to a recent low of $326.10 on March 31, 2026. Short-term performance has been notably weak, with the stock down 15.19% over the past month, significantly underperforming the S&P 500, which fell only 5.25% over the same period. The three-month performance is also negative at -6.51%, again underperforming the broader market's -4.63% decline. The current price of $328.59 is near the bottom of its 52-week range of $319.32 to $404.87, sitting just 2.9% above the 52-week low. This positioning indicates the stock is in a deeply oversold territory relative to its recent trading history.
Beta
0.87
0.87x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$319-$405
Price range past year
Annual Return
-11.8%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -14.9% | -3.7% |
| 3m | -6.3% | -4.1% |
| 6m | -11.1% | -2.1% |
| 1y | -11.8% | +16.1% |
| ytd | -5.4% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Revenue growth remains solid, with Q4 2025 revenue of $7.17 billion representing an 11.4% year-over-year increase. Profitability metrics are healthy, with a Q4 net margin of 11.8% and a gross margin of 65.2%, though operating income saw some pressure in Q3 2025. The company maintains a strong financial position with a current ratio of 1.89 and a manageable debt-to-equity ratio of 0.66. Free cash flow generation is robust, with TTM free cash flow of $4.28 billion, supporting operational flexibility and shareholder returns. Operational efficiency is demonstrated by a return on equity (ROE) of 14.5% and a return on assets (ROA) of 7.9%, indicating effective use of shareholder capital and company assets.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E ratio is elevated at 41.4, while the forward P/E is more reasonable at 19.6, based on estimated EPS of $22.82. This forward multiple suggests the market is pricing in future earnings growth. The Price/Sales ratio of 5.35 and EV/EBITDA of 23.0 provide additional context, though peer comparison data is not available in the provided inputs to assess relative valuation.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.0x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation, with a trailing P/E of 41.4 and EV/EBITDA of 23.0 significantly above market averages, making the stock vulnerable to multiple compression if growth expectations falter. Market and technical risks are pronounced, as the stock is in a sharp downtrend, underperforming the S&P 500 by a wide margin over the past month and year, and sits near its 52-week low, indicating persistent selling pressure. Operational and sector risks include potential pressure on operating margins, as seen in Q3 2025, and general sensitivity to healthcare spending, regulatory changes, and competitive dynamics in the medical device industry. While the company's strong balance sheet (current ratio 1.89) mitigates financial risk, the high PEG ratio of 5.16 underscores the market's elevated growth expectations, which, if not met, could lead to further downside.
FAQ
Key risks include: 1) Valuation risk, with high multiples (P/E 41.4, EV/EBITDA 23.0) vulnerable to compression. 2) Technical and market risk, as the stock is in a severe downtrend and underperforming the S&P 500. 3) Execution risk, where any slowdown in revenue growth or margin pressure could significantly impact the stock price given high expectations.
The 12-month outlook presents a base case target range of $350-$380, representing a 6.5% to 15.6% upside from the current price of $328.59. This assumes the company meets its estimated EPS and the forward P/E multiple of ~19.6x holds. The bull case targets a return to prior highs ($404+), while the bear case sees a retest of the 52-week low near $319.
SYK appears overvalued on a trailing basis but reasonably valued looking forward. The trailing P/E of 41.4 is very high, but the forward P/E of 19.6, based on estimated EPS of $22.82, is more in line with growth expectations. The high PEG ratio of 5.16, however, suggests the stock's growth premium is already fully priced in by the market.
SYK is a 'Hold' based on current data. The company's fundamentals are excellent with 11.4% revenue growth and strong cash flow. However, the stock is in a sharp downtrend, down 15% in a month, and trades at a high trailing P/E of 41.4. It may become a good buy if the price stabilizes or the valuation becomes more attractive relative to growth.
SYK is more suitable for long-term investors who can tolerate volatility. The company's strong market position and financials support a long-term growth story. However, the severe near-term technical weakness and high valuation make it a challenging short-term trade, as the stock may remain under pressure until the downtrend is broken.